Remission of Philadelphia positive chronic myelogenous leukemia associated with t(3;21) after bone marrow transplantation.
We here report a male patient with an additional t(3;21)(q26;q22) in Philadelphia positive chronic myelogenous leukemia (Ph + CML). In spite of the presence of this progression of disease marker and probably related to alpha-interferon therapy, this case entered into remission as a second chronic phase. At that time, he underwent allogeneic bone marrow transplantation. One year after BMT he showed a disappearance of leukemic clones at the cytogenetic and molecular levels. At present the patient has 21 months of clinical and hematologic remission. It is of interest to note that the association of alpha-interferon-hydroxyurea and bone marrow transplantation might produce a negative selection pressure against the leukemic clone in this patient.
Uriarte
M R
MR
División Citogenética, Instituto de Investigaciones Biológicas Clemente Estable, Montevideo, Uruguay.
Mori
M A
MA
de Bellis
R
R
Cardoso
H
H
D000328:Adult; D015139:Blotting, Southern; D016026:Bone Marrow Transplantation; D017024:Chemotherapy, Adjuvant; D002891:Chromosomes, Human, Pair 21; D002892:Chromosomes, Human, Pair 22; D002893:Chromosomes, Human, Pair 3; D002899:Chromosomes, Human, Pair 9; D004273:DNA, Neoplasm / Q000032:analysis; D006801:Humans; D006918:Hydroxyurea / Q000627:therapeutic use; D016898:Interferon-alpha / Q000627:therapeutic use; D007621:Karyotyping; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy / Q000235:genetics* / Q000601:surgery; D008297:Male; D012074:Remission Induction; D014178:Translocation, Genetic
D004273:DNA, Neoplasm; D016898:Interferon-alpha; D006918:Hydroxyurea